oncozine.com
Datopotamab deruxtecan (Datroway®; Daiichi Sankyo, previously known as DS-1062 and TROP2 ADC, see ADC Drug Map) an antibody-drug conjugate or ADC, being jointly developed and commercialized globally by Daiichi Sankyo and AstraZeneca, has been approved in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer after prior chemotherapy.
4 months ago
oncozine.com
In 2022, with an estimated 2.3 million new cases and nearly 700.000 deaths globally, breast cancer emerged as the most prevalent cancer after lung cancer. [1] Approximately 15–25% of patients diagnosed with breast cancer exhibit overexpression or amplification of human epidermal growth factor receptor 2 (HER2), which is characterized by high invasiveness and generally an […]
4 months ago
oncozine.com
Drinking Coffee and Tea and the Prevention of Cancer
4 months ago
Media DatabaseFind the right journalists
Online NewsroomShape your own narrative
Press Release CreatorCreate and send press releases
Media MonitoringTrack every single online mention
Media Pitching ToolContact recommendations & stats
PR ReportsShowcase the impact of your work
PR CRMManage contacts in easy way
AI PR SoftwareUse AI to save time on your workflow
Social Media ListeningGet a full overview of your brand's presence